vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $31.4M, roughly 1.2× Ponce Financial Group, Inc.). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -3.7%, a 40.0% gap on every dollar of revenue. On growth, Ponce Financial Group, Inc. posted the faster year-over-year revenue change (37.6% vs 33.4%). Ponce Financial Group, Inc. produced more free cash flow last quarter ($54.6M vs $-5.8M). Over the past eight quarters, Ponce Financial Group, Inc.'s revenue compounded faster (23.7% CAGR vs 17.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
GYRE vs PDLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $31.4M |
| Net Profit | $-1.4M | $10.1M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 43.6% |
| Net Margin | -3.7% | 36.3% |
| Revenue YoY | 33.4% | 37.6% |
| Net Profit YoY | -340.1% | 245.6% |
| EPS (diluted) | $-0.01 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $31.4M | ||
| Q3 25 | $30.6M | $26.7M | ||
| Q2 25 | $26.8M | $26.5M | ||
| Q1 25 | $22.1M | $24.6M | ||
| Q4 24 | $27.9M | $22.8M | ||
| Q3 24 | $25.5M | $20.2M | ||
| Q2 24 | $25.2M | $20.2M | ||
| Q1 24 | $27.2M | $20.5M |
| Q4 25 | $-1.4M | $10.1M | ||
| Q3 25 | $5.9M | $6.5M | ||
| Q2 25 | $1.6M | $6.1M | ||
| Q1 25 | $3.7M | $6.0M | ||
| Q4 24 | $569.0K | $2.9M | ||
| Q3 24 | $2.9M | $2.4M | ||
| Q2 24 | $4.5M | $3.2M | ||
| Q1 24 | $9.9M | $2.4M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 43.6% | ||
| Q3 25 | 22.7% | 32.8% | ||
| Q2 25 | 8.1% | 30.2% | ||
| Q1 25 | 10.3% | 32.5% | ||
| Q4 24 | 2.4% | 19.6% | ||
| Q3 24 | 16.6% | 15.2% | ||
| Q2 24 | 12.7% | 21.8% | ||
| Q1 24 | 29.7% | 18.3% |
| Q4 25 | -3.7% | 36.3% | ||
| Q3 25 | 19.4% | 24.3% | ||
| Q2 25 | 5.9% | 23.0% | ||
| Q1 25 | 16.9% | 24.2% | ||
| Q4 24 | 2.0% | 14.1% | ||
| Q3 24 | 11.2% | 12.1% | ||
| Q2 24 | 18.0% | 15.8% | ||
| Q1 24 | 36.6% | 11.8% |
| Q4 25 | $-0.01 | $0.43 | ||
| Q3 25 | $0.03 | $0.27 | ||
| Q2 25 | $0.00 | $0.25 | ||
| Q1 25 | $0.00 | $0.25 | ||
| Q4 24 | $0.00 | $0.11 | ||
| Q3 24 | $0.01 | $0.10 | ||
| Q2 24 | $0.01 | $0.14 | ||
| Q1 24 | $0.03 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $126.2M |
| Total DebtLower is stronger | — | $596.1M |
| Stockholders' EquityBook value | $106.0M | $541.5M |
| Total Assets | $166.1M | $3.2B |
| Debt / EquityLower = less leverage | — | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $126.2M | ||
| Q3 25 | $60.0M | $146.6M | ||
| Q2 25 | $54.4M | $126.6M | ||
| Q1 25 | $29.9M | $129.9M | ||
| Q4 24 | $26.7M | $139.8M | ||
| Q3 24 | $25.1M | $155.8M | ||
| Q2 24 | $25.1M | $103.2M | ||
| Q1 24 | $37.4M | $134.7M |
| Q4 25 | — | $596.1M | ||
| Q3 25 | — | $521.1M | ||
| Q2 25 | — | $536.1M | ||
| Q1 25 | — | $521.1M | ||
| Q4 24 | — | $596.1M | ||
| Q3 24 | — | $580.4M | ||
| Q2 24 | — | $680.4M | ||
| Q1 24 | — | $680.4M |
| Q4 25 | $106.0M | $541.5M | ||
| Q3 25 | $101.9M | $529.8M | ||
| Q2 25 | $92.0M | $521.1M | ||
| Q1 25 | $68.1M | $513.9M | ||
| Q4 24 | $63.3M | $505.5M | ||
| Q3 24 | $63.2M | $504.6M | ||
| Q2 24 | $60.4M | $497.7M | ||
| Q1 24 | $56.6M | $493.7M |
| Q4 25 | $166.1M | $3.2B | ||
| Q3 25 | $159.4M | $3.2B | ||
| Q2 25 | $152.6M | $3.2B | ||
| Q1 25 | $129.8M | $3.1B | ||
| Q4 24 | $125.4M | $3.0B | ||
| Q3 24 | $125.2M | $3.0B | ||
| Q2 24 | $120.9M | $2.8B | ||
| Q1 24 | $122.0M | $2.8B |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $55.6M |
| Free Cash FlowOCF − Capex | $-5.8M | $54.6M |
| FCF MarginFCF / Revenue | -15.5% | 173.9% |
| Capex IntensityCapex / Revenue | 0.4% | 3.1% |
| Cash ConversionOCF / Net Profit | — | 5.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $74.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $55.6M | ||
| Q3 25 | $4.7M | $1.4M | ||
| Q2 25 | $2.1M | $6.2M | ||
| Q1 25 | $-129.0K | $13.1M | ||
| Q4 24 | $-2.8M | $7.2M | ||
| Q3 24 | $1.7M | $-14.6M | ||
| Q2 24 | $-5.5M | $-2.6M | ||
| Q1 24 | $2.9M | $1.5M |
| Q4 25 | $-5.8M | $54.6M | ||
| Q3 25 | $4.0M | $786.0K | ||
| Q2 25 | $1.8M | $5.9M | ||
| Q1 25 | $-251.0K | $12.9M | ||
| Q4 24 | $-2.8M | $4.5M | ||
| Q3 24 | $1.0M | $-15.0M | ||
| Q2 24 | $-6.9M | $-2.6M | ||
| Q1 24 | $2.7M | $-315.0K |
| Q4 25 | -15.5% | 173.9% | ||
| Q3 25 | 13.1% | 2.9% | ||
| Q2 25 | 6.8% | 22.4% | ||
| Q1 25 | -1.1% | 52.6% | ||
| Q4 24 | -10.1% | 19.7% | ||
| Q3 24 | 4.1% | -74.1% | ||
| Q2 24 | -27.5% | -13.0% | ||
| Q1 24 | 9.8% | -1.5% |
| Q4 25 | 0.4% | 3.1% | ||
| Q3 25 | 2.2% | 2.3% | ||
| Q2 25 | 1.0% | 1.0% | ||
| Q1 25 | 0.6% | 0.6% | ||
| Q4 24 | 0.2% | 11.9% | ||
| Q3 24 | 2.7% | 2.0% | ||
| Q2 24 | 5.8% | 0.3% | ||
| Q1 24 | 0.9% | 8.7% |
| Q4 25 | — | 5.48× | ||
| Q3 25 | 0.79× | 0.21× | ||
| Q2 25 | 1.32× | 1.01× | ||
| Q1 25 | -0.03× | 2.20× | ||
| Q4 24 | -4.85× | 2.46× | ||
| Q3 24 | 0.60× | -5.99× | ||
| Q2 24 | -1.21× | -0.80× | ||
| Q1 24 | 0.29× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
